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Effect of Glucocorticoids on the Clinical and
Radiographic Efficacy of Tofacitinib in Patients with
Rheumatoid Arthritis: A Posthoc Analysis of Data from
6 Phase III Studies
Christina Charles-Schoeman, Désirée van der Heijde, Gerd R. Burmester, Peter Nash, 
Cristiano A.F. Zerbini, Carol A. Connell, Haiyun Fan, Kenneth Kwok, Eustratios Bananis, 
and Roy Fleischmann
ABSTRACT. Objective. Tofacitinib has been investigated for the treatment of rheumatoid arthritis (RA) in phase
III studies in which concomitant glucocorticoids (GC) were allowed. We analyzed the effect of GC
use on efficacy outcomes in patients with RA receiving tofacitinib and/or methotrexate (MTX) or
conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in these studies.
Methods. Our posthoc analysis included data from 6 phase III studies (NCT01039688; NCT00814307;
NCT00847613; NCT00853385; NCT00856544; NCT00960440). MTX-naive patients or patients
with inadequate response to csDMARD or biological DMARD received tofacitinib 5 or 10 mg twice
daily alone or with csDMARD, with or without concomitant GC. Patients receiving GC (≤ 10 mg/day
prednisone or equivalent) before enrollment maintained a stable dose throughout. Endpoints included
the American College of Rheumatology (ACR) 20/50/70 response rates, rates of Clinical Disease
Activity Index (CDAI)-defined low disease activity (LDA; CDAI ≤ 10) and remission (CDAI ≤ 2.8),
and changes from baseline in CDAI, 28-joint count Disease Activity Score (DAS28-4)–erythrocyte
sedimentation rate (ESR), Health Assessment Questionnaire–Disability Index (HAQ-DI), pain visual
analog scale (VAS), and modified total Sharp score.
Results. Of 3200 tofacitinib-treated patients, 1258 (39.3%) received tofacitinib monotherapy and
1942 (60.7%) received tofacitinib plus csDMARD; 1767 (55.2%) received concomitant GC.
ACR20/50/70 response rates, rates of CDAI LDA and remission, and improvements in CDAI,
DAS28-4-ESR, HAQ-DI, and pain VAS with tofacitinib were generally similar with or without GC
in monotherapy and combination therapy studies. GC use did not appear to affect radiographic
progression in tofacitinib-treated MTX-naive patients. MTX plus GC appeared to inhibit radiographic
progression to a numerically greater degree than MTX alone.
Conclusion. Concomitant use of GC with tofacitinib did not appear to affect clinical or radiographic
efficacy. MTX plus GC showed a trend to inhibit radiographic progression to a greater degree than
MTX alone. (First Release November 15 2017; J Rheumatol 2018;45:177–87; doi:10.3899/
jrheum.170486)
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Rheumatoid arthritis (RA) is a chronic autoimmune disease
that is estimated to affect about 0.24% of the population
worldwide1. Characterized by systemic inflammation,
persistent synovitis, and joint destruction2, RA has the
potential to have a significant effect on functional ability,
with reduction in quality of life and work and social
productivity3.
    The goal of the treat-to-target approach for RA is to achieve
remission; however, low disease activity (LDA) is acceptable
if remission cannot be achieved4. To rapidly control pain and
inflammation while awaiting the effects of other dis-
ease-modifying antirheumatic drug (DMARD) treatments,
patients with RA often initially receive concomitant treatment
with oral glucocorticoids (GC). Many rheumatology societies
recommend the use of GC in combination with DMARD, with
GC being tapered as soon as is clinically feasible4,5,6,7,8. 
    Tofacitinib is an oral Janus kinase inhibitor for the
treatment of RA. The efficacy and safety of tofacitinib 5 and
10 mg twice daily (BID), administered as monotherapy 
or in combination with conventional synthetic DMARD
(csDMARD), mainly methotrexate (MTX), in patients with
moderate to severe active RA have been demonstrated in
phase II9,10,11,12,13 and phase III14,15,16,17,18,19 studies of up
to 24 months duration and in longterm extension studies with
up to 105 months of observation20,21,22. The safety of tofa-
citinib administered as monotherapy or in combination with
csDMARD, with and without concomitant GC treatment, has
been previously evaluated in the phase III program23,24,25. 
    In the posthoc analysis reported here, we investigated the
effect of concomitant GC use on clinical and radiographic
outcomes in 6 phase III studies of tofacitinib versus MTX or
placebo as monotherapy or in combination with csDMARD in
patients with RA. Unlike studies that evaluated the effec-
tiveness of initial GC therapy as part of the therapeutic strategy,
our analysis included patients who were receiving GC prior to
the start of their respective clinical trial, the dose of which was
required to be maintained throughout their study26,27,28.
MATERIALS AND METHODS
Study design. Our posthoc analysis included data from 6 randomized,
double-blind phase III studies of tofacitinib in patients with RA stratified by
GC use at baseline (Supplementary Figure 1, available with the online
version of this article).
      Two studies evaluated tofacitinib 5 and 10 mg BID as monotherapy:
ORAL Start (NCT01039688), a 24-month study of tofacitinib versus MTX
in patients who were MTX-naive (n = 956)17, and ORAL Solo
(NCT00814307), a 6-month study of tofacitinib versus placebo in patients
(n = 610) with an inadequate response (IR) to ≥ 1 csDMARD or biologic
DMARD (DMARD-IR)15.
      Four studies evaluated tofacitinib 5 and 10 mg BID in combination with
csDMARD versus placebo plus csDMARD: ORAL Scan (NCT00847613),
a 24-month study of tofacitinib in MTX-IR (n = 797) receiving background
MTX18; ORAL Standard (NCT00853385), a 12-month study in patients with
MTX-IR (n = 717) receiving background MTX19; ORAL Sync
(NCT00856544), a 12-month study of tofacitinib in patients with
DMARD-IR (n = 792) who were receiving background csDMARD16; and
ORAL Step (NCT00960440), a 6-month study in patients (n = 399) who had
an IR to tumor necrosis factor inhibitors (TNFi) and were receiving
background MTX14. All patients who were receiving oral GC (≤ 10 mg/day
of prednisone or equivalent) prior to enrollment in the studies were required
to remain on their baseline dose throughout the studies.
      In ORAL Solo and ORAL Step, all patients receiving placebo advanced
blindly to tofacitinib 5 or 10 mg BID at Month 3. In the other studies, patients
receiving placebo who did not respond at Month 3 (< 20% reduction from
baseline in swollen and tender joint counts) were advanced blindly to tofa-
citinib 5 or 10 mg BID; at Month 6, all remaining placebo patients were
advanced to tofacitinib. 
      All studies were conducted in accordance with the Good Clinical
Practice Guidelines of the International Conference on Harmonisation, the
Declaration of Helsinki, and the local country regulations. The study
protocols were approved by the institutional review board or the independent
ethics committee at each site14,15,16,17,18,19. All patients provided written
informed consent. No further ethical approval was required to conduct the
analysis in our report, in accordance with the policy of our institutions.
Patients. Inclusion and exclusion criteria have been described previ-
ously14,15,16,17,18,19. Briefly, eligible patients were aged ≥ 18 years with a
diagnosis of RA and met the American College of Rheumatology (ACR)
1987 Revised RA Classification Criteria. Active disease was defined as the
presence of ≥ 6 tender or painful joints (out of 68 specific joints examined)
and ≥ 6 swollen joints (out of 66 specific joints examined; ≥ 4 for each in
ORAL Sync) and erythrocyte sedimentation rate (ESR; Westergren method)
> 28 mm/h, or high-sensitivity C-reactive protein level > 7 mg/l.
Assessments and outcomes. For the purposes of our posthoc analysis,
efficacy was assessed at months 3, 6, 12, and 24 for ORAL Start, and at
Month 3 for ORAL Solo and the pooled combination studies owing to
placebo-treated patients advancing to tofacitinib at Month 3 in these studies.
Therefore, outcomes for ORAL Start, ORAL Solo, and the pooled combi-
nation therapy studies are presented as separate groups for these reasons.
Outcomes included the percentage of patients achieving ACR20, ACR50,
or ACR70 responses (defined as an improvement from baseline of ≥ 20%, 
≥ 50%, and ≥ 70%, respectively, in the number of tender and swollen joints,
and at least 3 of the 5 ACR core component measures), and Clinical Disease
Activity Index (CDAI)–defined LDA (CDAI ≤ 10) and remission (CDAI 
≤ 2.8). Radiographic progression is reported for ORAL Start only, based on
the change from baseline of ≤ 0.5 in the van der Heijde modified total Sharp
score (mTSS, defined as no radiographic progression). The scoring of the
radiographs was performed by 2 separate, central, blinded assessors.
Changes from baseline in CDAI, 28-joint Disease Activity Score using the
ESR (DAS28-4-ESR), Health Assessment Questionnaire–Disability Index
(HAQ-DI), mTSS (ORAL Start only; mTSS data for ORAL Scan were not
included in our posthoc analysis owing to the lack of a placebo arm
post-months 3 and 6), and pain visual analog scale (VAS) were also
evaluated. 
Statistical analyses. Data from the 2 phase III monotherapy studies (ORAL
Start and ORAL Solo) were analyzed individually, whereas data from the 4
combination therapy studies (ORAL Scan, ORAL Standard, ORAL Sync,
and ORAL Step) were pooled for analysis. Unless otherwise stated, all
efficacy analyses were based on the full analysis set, which included all
patients who were randomized to the study and received ≥ 1 dose of the
study drug. The analysis was based on concomitant baseline GC use; because
of the design of the study, patients were required to maintain a stable GC
dose throughout the study and initiation of a new GC agent was not allowed
during the study.
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      Within each study cohort, disease activity in the tofacitinib treatment
groups were compared with the respective comparator arm (MTX or placebo).
These posthoc analyses were exploratory, with no multiplicity adjustments
applied. A p value < 0.05 was considered statistically significant.
      For the binary (response) endpoints, comparisons were performed
between tofacitinib and the comparator arm using the normal approximation
to the binomial proportions and missing data were imputed using non-
responder imputation. Linear mixed-effect models were used to assess
treatment effect over the comparator arm for continuous variables; missing
data were handled within the model. Linear extrapolation was used to impute
missing mTSS values in the tofacitinib and MTX treatment groups for
ORAL Start. 
RESULTS
Patients. A total of 4067 patients were included in our
analysis, of whom 3200 patients received tofacitinib 5 or 
10 mg BID, 186 received initial MTX monotherapy in ORAL
Start, and 681 received placebo (Supplementary Table 1,
Supplementary Figure 1; available with the online version of
this article). Of the total patients, 1566 participated in the
monotherapy studies (ORAL Start and ORAL Solo). Of the
956 patients from ORAL Start, 373, 397, and 186 received
tofacitinib 5 and 10 mg BID and tofacitinib placebo, respec-
tively. All patients (n = 610) from ORAL Solo were included
in our analysis, with 243, 245, and 122 patients receiving
tofacitinib 5 and 10 mg BID and placebo, respectively. Of the
2501 patients who received tofacitinib or placebo in the
pooled phase III combination studies, 973, 969, and 559
patients received tofacitinib 5 and 10 mg BID and placebo,
respectively.
    Concomitant oral GC was received by 445 (46.5%)
patients in ORAL Start, 350 (57.4%) in ORAL Solo, and
1454 (58.1%) in the pooled phase III combination studies
(Supplementary Table 1; Supplementary Figure 1, available
in the online version of this article). Patients received a mean
GC dose range of 6.2–8.3, 6.4–7.0, and 6.1–6.3 mg/day in
ORAL Start, ORAL Solo, and the pooled phase III combi-
nation studies, respectively. 
    Patient baseline demographics and disease characteristics
were generally similar across all of the phase III studies
(Supplementary Table 1, available with the online version of
this article) other than patients from ORAL Start having a
shorter mean RA disease duration (2.5–3.7 yrs) than patients
in other phase III studies (ORAL Solo: 6.6–9.1 yrs; pooled
combination therapy studies: 8.8–10.5 yrs), and the percentage
of placebo patients in ORAL Solo who were rheumatoid
factor–positive (RF+; 52.5%) was lower than in the pooled
phase III  studies (70.5%). Patient baseline demographics and
disease characteristics were also generally similar regardless
of whether patients were receiving GC at baseline, although
mean C-reactive protein (CRP) at baseline and percentage of
patients who were positive for anticyclic citrullinated peptide
antibodies (anti-CCP) and RF, or who had CRP > 7 mg/l, were
generally higher for patients with DMARD-IR (ORAL Solo)
receiving GC than for those not receiving GC at baseline.
Among the 4 pooled combination therapy studies, patient
baseline demographics and disease characteristics were
generally similar, with a few exceptions, such as patients from
ORAL Step previously failing treatment with TNFi and
having longer mean disease duration compared with the other
3 studies (11.3–13.0 vs 6.9–10.2 yrs)14,16,18,19.
Clinical and radiographic efficacy results in ORAL Start.
Similar ACR20, ACR50, and ACR70 response rates were seen
at months 6 and 24, irrespective of GC use, in patients
receiving tofacitinib 5 or 10 mg BID or MTX (Figure 1).
MTX-treated patients receiving GC achieved numerically
higher ACR20 and ACR50 response rates at months 6 and 24
compared with those patients not receiving GC (with
overlapping 95% CI; Figure 1A). A greater percentage of
patients receiving either dose of tofacitinib achieved ACR20,
ACR50, and ACR70 responses compared with patients
receiving MTX, regardless of concomitant GC use (Figure 1). 
    At Month 24, the percentages of patients achieving CDAI
LDA (CDAI ≤ 10) and remission (CDAI ≤ 2.8) with tofa-
citinib 5 mg or 10 mg BID were similar regardless of whether
patients were receiving GC (Figure 2). Although the
percentages of patients achieving CDAI LDA and remission
were also similar between patients receiving MTX regardless
of GC use, these were significantly lower (p < 0.05) than
patients receiving either dose of tofacitinib.
    At Month 3, the least squares mean (LSM) changes from
baseline in CDAI, HAQ-DI, DAS28-4-ESR, and pain VAS
were statistically greater for patients receiving either dose of
tofacitinib compared with MTX, regardless of GC use (Table
1). Further, LSM changes from baseline in these outcomes
were slightly greater, with overlapping 95% CI in patients
receiving either dose of tofacitinib without GC, compared
with those receiving GC (Table 1). 
    For both doses of tofacitinib, LSM changes from baseline
in mTSS through Month 24 were generally similar when
given with or without GC (Figure 3). However, the use of GC
in patients treated with MTX appeared to inhibit radiographic
progression to a greater extent than when GC were not used
(Figure 3A). Patients treated with MTX without GC had the
highest LSM change from baseline through Month 24 among
all the treatment groups; however, the 95% CI overlapped
between the 2 MTX subgroups. 
    Within each individual treatment group (tofacitinib 5 mg,
tofacitinib 10 mg, and MTX), the percentage of patients with
no radiographic progression at Month 24 were similar,
irrespective of GC use (Figure 4). Further, a greater percentage
of patients had no radiographic progression with tofacitinib
compared with MTX, regardless of concomitant GC use. 
Clinical efficacy results in ORAL Solo and pooled phase III
studies of tofacitinib plus csDMARD. At Month 3, the ACR20,
ACR50, and ACR70 response rates, and the percentage of
patients achieving CDAI LDA and remission (for patients
receiving tofacitinib 5 or 10 mg BID or placebo) were numer-
ically similar (with overlapping 95% CI) between patients
receiving GC and those not receiving GC (Table 2A, B). A
greater percentage of patients achieved the above endpoints
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Figure 1. ACR20/50/70 response rates through Month 24 in
patients receiving (A) MTX; (B) tofacitinib 5 mg BID; or 
(C) tofacitinib 10 mg BID ± GC in ORAL Start (FAS, NRI). 
*p < 0.05; **p < 0.001; ***p < 0.0001 (without multiplicity
adjustment for exploratory analysis) vs MTX within the
respective subgroup. ACR20/50/70: improvement of ≥ 20%,
≥ 50%, and ≥ 70%, respectively, in the American College of
Rheumatology criteria; BID: twice daily; FAS: full analysis
set; GC: glucocorticoids; MTX: methotrexate; NRI: non-
responder imputation.
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Figure 2. Rates of CDAI LDA (CDAI ≤ 10) and CDAI
remission (CDAI ≤ 2.8) in patients receiving (A) MTX; 
(B) tofacitinib 5 mg BID; or (C) tofacitinib 10 mg BID ± GC
in ORAL Start (FAS, NRI). *p < 0.05; **p < 0.001; ***p <
0.0001 (without multiplicity adjustment for exploratory
analysis) vs MTX within the respective subgroup. BID: twice
daily; CDAI: Clinical Disease Activity Index; FAS: full
analysis set; GC: glucocorticoids; LDA: low disease activity;
MTX: methotrexate; NRI: nonresponder imputation.
 of Rheumatology
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with both doses of tofacitinib compared with placebo with or
without csDMARD. Improvements from baseline in CDAI,
HAQ-DI, DAS28-4-ESR, and pain VAS were also similar at
Month 3 between tofacitinib-treated patients, with or without
GC, although improvements tended to be numerically greater
in patients not receiving GC (Table 2A, B). 
DISCUSSION
The objective of our posthoc analysis was to examine the
effect of GC on RA clinical and radiographic (ORAL Start
only) outcomes in phase III studies of MTX-naive patients
receiving tofacitinib or MTX as monotherapy (ORAL Start),
patients with DMARD-IR receiving tofacitinib or placebo as
monotherapy (ORAL Solo), and in patients with MTX-IR
and DMARD-IR receiving tofacitinib or placebo in combi-
nation with background csDMARD14,15,16,17,18,19. Among
these patients, those who used GC at baseline maintained the
same GC dose throughout their study participation. To our
knowledge, this is the first developmental drug program in
RA to examine the effects of concomitant GC treatment in
this patient population, and the first analysis to examine the
efficacy of tofacitinib with and without concomitant baseline
GC in a large phase III program. Our analysis differs from
other studies that compare the efficacy of different RA treat-
ments with and without GC as part of the initial therapeutic
strategy, in that patients in our analysis did not initiate GC at
baseline but instead had used GC through baseline while still
having active disease at baseline.
    Across all 6 phase III studies, the concomitant use of GC
did not appear to affect the clinical efficacy of tofacitinib.
Generally, similar rates of ACR20, ACR50, and ACR70
responses, and CDAI LDA and remission, were observed in
tofacitinib-treated patients receiving GC compared with those
who did not receive GC. Additionally, although GC such as
prednisone have also been reported to inhibit radiographic
progression in patients with RA29,30,31, the concomitant use
of GC did not affect the radiographic efficacy and rate of
radiographic nonprogression in tofacitinib-treated patients in
ORAL Start. A trend was observed, however, for greater
inhibition of radiographic progression when MTX was given
with GC compared with MTX alone in ORAL Start. This
trend is in line with previous studies, which have found that
MTX plus low-dose GC results in better clinical and struc-
tural outcomes28,32 than MTX alone. The overlapping 95%
CI between the 2 MTX subgroups may have been a result of
the small sample size.
    In general, response rates for ACR20, ACR50, ACR70,
and CDAI LDA, as well as improvements in CDAI score,
were numerically higher in placebo plus csDMARD-treated
non-tofacitinib patients who received GC in the 4 phase III
tofacitinib combination therapy studies, compared with those
who did not; however, 95% CI overlapped. This may be a
consequence of the small sample size in our analysis, and
may also reflect that patients in our analysis were continuing
rather than starting GC treatment. The results are consistent
with several studies that have demonstrated that the treatment
of early RA with csDMARD in combination with GC results
in faster and more persistent disease control than csDMARD
alone. Patients in the BARFOT GC study who received
prednisolone together with DMARD showed higher
remission rates and reduced radiographic progression after 4
years compared with csDMARD-treated patients who did not
receive prednisolone33. Similarly, in the Care in Early RA
(CareRA) trial, more patients who received MTX with oral
GC achieved remission and clinically meaningful HAQ
responses by Week 16 compared with patients who received
MTX without oral GC27. In the Computer Assisted
Management in early Rheumatoid Arthritis II (CAMERA-II)
trial, MTX therapy together with GC resulted in more rapid
improvement in DAS28, ESR, pain VAS, and HAQ versus
MTX with placebo28. However, it is important to note that
unlike the phase III combination therapy studies reported here
in which patients who enrolled in the trial were already
receiving GC, patients in these studies were not receiving GC
prior to the start of the studies.
    The effect of GC use with other RA medications such 
as biological DMARD (bDMARD) has also been
analyzed34,35,36; however, the results of studies involving GC
and bDMARD are less clear than those of csDMARD. There
are conflicting reports regarding the concomitant use of GC
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Table 1. LSM change from baseline in CDAI, HAQ-DI, DAS28-4-ESR, and pain VAS at Month 3 in patients receiving MTX, tofacitinib 5 or 10 mg BID ± GC
in ORAL Start (FAS). Values are LSM change (95% CI).
Variables                                               MTX                                                               Tofacitinib 5 mg BID                                                   Tofacitinib 10 mg BID
                                  + GC, n = 78a                          – GC, n = 91a                          + GC, n = 172a                          – GC, n = 179a                         + GC, n = 165a                          – GC, n = 214a
CDAI                  –16.4 (–18.8 to –13.9)      –18.1 (–20.1 to –16.1)    –22.8*** (–24.5 to –21.1)  –24.7*** (–26.1 to –23.2) –24.5*** (–26.2 to –22.7)  –26.1*** (–27.4 to –24.8)
HAQ–DI                –0.5 (–0.6 to –0.4)            –0.5 (–0.6 to –0.4)            –0.7* (–0.8 to –0.7)           –0.8** (–0.9 to –0.7)        –0.8*** (–0.9 to –0.7)        –0.9*** (–1.0 to –0.8)
DAS28-4-ESR       –1.5 (–1.8 to –1.2)            –1.6 (–1.9 to –1.4)          –2.3*** (–2.5 to –2.1)        –2.5*** (–2.6 to –2.3)       –2.5*** (–2.7 to –2.3)        –2.7*** (–2.9 to –2.5)
Pain VAS            –19.8 (–24.8 to –14.8)      –25.8 (–29.8 to –21.7)      –29.3* (–32.7 to –25.9)      –30.9* (–33.8 to –28.0)    –30.8** (–34.2 to –27.3)    –34.6** (–37.3 to –31.9)
*p < 0.05; **p < 0.001; ***p < 0.0001 (without multiplicity adjustment for exploratory analysis) vs MTX within the respective subgroup. an based on HAQ-DI
endpoint; however, patient numbers varied between outcome measures. BID: twice daily; CDAI: Clinical Disease Activity Index; DAS28-4-ESR: 28-joint
Disease Activity Score using the erythrocyte sedimentation rate; FAS: full analysis set; GC: glucocorticoids; HAQ-DI: Health Assessment 
Questionnaire–Disability Index; LSM: least squares mean; MTX: methotrexate; VAS: visual analog scale. 
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Figure 3. LSM changes from baseline in mTSS in ORAL Start
for patients receiving (A) MTX; (B) tofacitinib 5 mg BID; or 
(C) tofacitinib 10 mg BID ± GC (FAS). *p < 0.05; **p < 0.001
(without multiplicity adjustment for exploratory analysis) vs
MTX within the respective subgroup. BID: twice daily; FAS: full
analysis set; GC: glucocorticoids; LSM: least squares mean;
mTSS: modified total Sharp score; MTX: methotrexate.
 of Rheumatology
The Journal on August 23, 2019 - Published by www.jrheum.orgDownloaded from 
184 The Journal of Rheumatology 2018; 45:2; doi:10.3899/jrheum.170486
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2018. All rights reserved.
Figure 4. Percentage of radiographic nonprogressors in ORAL
Start for patients receiving (A) MTX; (B) tofacitinib 5 mg BID;
or (C) tofacitinib 10 mg BID ± GC (FAS, NRI). *p < 0.05; 
**p < 0.001 (without multiplicity adjustment for exploratory
analysis) vs MTX within the respective subgroup. BID: twice
daily; FAS: full analysis set; GC: glucocorticoids; MTX:
methotrexate; NRI: nonresponder imputation.
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with TNFi treatment. One  study states that concomitant GC
use is a predictor of decreased clinical response and remission
in TNFi treatment36, whereas another demonstrates that the use
of GC was associated with higher odds of achieving remission
in patients treated with TNFi35. GC use prior to the enrollment
of patients was not specified in the inclusion and exclusion
criteria of these studies. Tocilizumab and abatacept have shown
GC-sparing effects, in that the dose of GC may be reduced
while the patient is receiving bDMARD without inhibiting
clinical improvement in disease activity37,38. Similarly,
because the efficacy of tofacitinib may not be affected by
concomitant GC therapy, it is possible that patients using both
treatments may be able to reduce the dose of GC. A properly
designed study would be needed to confirm these findings.
    The effect of concomitant GC use on the safety profile of
tofacitinib has previously been assessed23,24,25. Rates of
serious adverse events, discontinuation as a result of adverse
events, serious infection events, and herpes zoster were
shown to be increased in patients treated with tofacitinib who
received concomitant GC compared with those who did
not23,24,25. The results of our exploratory posthoc analysis
suggest that the efficacy of tofacitinib is not affected by
background GC use; however, further research is required to
determine whether GC use can be tapered following the initi-
ation of tofacitinib, to reduce the risk of adverse events while
maintaining efficacy.
    Limitations of our analysis include that it was performed
posthoc, and the studies were not designed to compare
efficacy and radiographic progression (ORAL Start only) in
patients with and without concomitant GC use; therefore, any
conclusions should be regarded as exploratory. Moreover, the
patients in our analysis had active RA at the commencement
of the studies despite receiving GC, indicating that they were
only partially responsive to GC therapy. These results,
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Table 2A. Percentage of patients achieving ACR20/50/70 responses and CDAI LDA (≤ 10) and remission (≤ 2.8), and LSM changes from baseline in CDAI,
HAQ-DI, DAS28-4-ESR, and pain VAS in patients receiving tofacitinib 5 or 10 mg BID ± GC at Month 3 in ORAL Solo. 
Variables                                             Placebo                                                          Tofacitinib 5 mg BID                                                       Tofacitinib 10 mg BID
                                  + GC, n = 71a                      – GC, n = 49a                         + GC, n = 139a                          – GC, n = 102a                             + GC n = 140a                            – GC, n = 102a
Patients, FAS, NRI, % (95% CI) 
ACR20                    28.2 (18.1–40.1)            24.5 (13.3–38.9)            57.6*** (48.9–65.9)           62.8*** (52.6–72.1)             61.4*** (52.8–69.5)            71.6*** (61.8–80.1)
ACR50                     12.7 (6.0–22.7)              12.2 (4.6–24.8)              31.7** (24.0–40.1)              30.4* (21.7–40.3)               35.7*** (27.8–44.3)             38.2** (28.8–48.4)
ACR70                      5.6 (1.6–13.8)                6.1 (1.3–16.9)                16.6* (10.8–23.8)                 13.7 (7.7–22.0)                   19.3* (13.1–26.8)                21.6* (14.0–30.8)
CDAI ≤ 10                 9.9 (4.1–19.3)               14.3 (5.9–27.2)              28.1** (20.8–36.3)              32.4* (23.4–42.3)                30.0** (22.6–38.3)              38.2** (28.8–48.4)
CDAI ≤ 2.8                 2.8 (0.3–9.8)                  0.0 (0.0–7.3)                    6.5 (3.0–11.9)                    4.9* (1.6–11.1)                      8.6 (4.5–14.5)                     7.8* (3.5–14.9)
LSM change from baseline (95% CI) 
CDAI                   –11.5 (–14.8 to –8.2)     –12.7 (–16.3 to –9.1)    –20.5*** (–22.7 to –18.2)  –21.9*** (–24.3 to –19.6)    –22.1*** (–24.4 to –19.8)   –25.0*** (–27.4 to –22.5)
HAQ–DI                –0.2 (–0.4 to –0.1)          –0.1 (–0.3 to 0.1)            –0.5* (–0.6 to –0.4)           –0.5** (–0.6 to –0.4)           –0.6*** (–0.7 to –0.5)          –0.5** (–0.6 to –0.4)
DAS28-4-ESR       –1.1 (–1.5 to –0.8)         –1.1 (–1.4 to –0.7)          –1.9** (–2.1 to –1.6)         –2.0*** (–2.3 to –1.8)          –2.0*** (–2.3 to –1.8)         –2.3*** (–2.6 to –2.0)
Pain VAS              –12.0 (–18.0 to –6.0)     –11.0 (–17.6 to –4.3)     –26.0** (–30.1 to –21.9)   –27.2*** (–31.6 to –22.8)    –28.0*** (–32.2 to –23.9)   –33.4*** (–37.9 to –28.9)
Table 2B. Percentage of patients achieving ACR20/50/70 responses and CDAI LDA (≤ 10) and remission (≤ 2.8), and LSM changes from baseline in CDAI,
HAQ-DI, DAS28-4-ESR, and pain VAS in patients receiving tofacitinib 5 or 10 mg BID ± GC at Month 3 in pooled studies of tofacitinib plus csDMARD.
Variables                                   Placebo + csDMARD                                    Tofacitinib 5 mg BID + csDMARD                                Tofacitinib 10 mg BID + csDMARD
                                + GC, n = 315a                 – GC, n = 231a                    + GC, n = 561a                            – GC, n = 384a                              + GC, n = 535a                             – GC, n = 410a
Patients, FAS, NRI, % (95% CI)
ACR20                   29.2 (24.2–34.6)          22.5 (17.3–28.5)          53.8*** (49.6–58.0)             57.0*** (51.9–62.0)               60.4*** (56.1–64.5)             63.2*** (58.3–67.9)
ACR50                     9.2 (6.3–13.0)              6.9 (4.0–11.0)            28.3*** (24.7–32.3)             30.2*** (25.7–35.1)               32.2*** (28.2–36.3)             32.9*** (28.4–37.7)
ACR70                      2.2 (0.9–4.5)                1.7 (0.5–4.4)              10.3*** (7.9–13.2)               11.2*** (8.2–14.8)                14.6*** (11.7–17.9)             15.1*** (11.8–19.0)
CDAI ≤ 10               11.5 (7.7–16.3)             7.8 (4.3–12.7)            27.7*** (23.8–32.0)             29.4*** (24.6–34.6)               32.4*** (28.2–36.9)             36.3*** (31.2–41.6)
CDAI ≤ 2.8                0.0 (0.0–1.6)                0.6 (0.0–3.1)                5.0*** (3.2–7.4)                    5.7** (3.5–8.8)                      5.2*** (3.4–7.6)                  7.8*** (5.2–11.1)
LSM change from baseline (95% CI)
CDAI                   –9.8 (–11.2 to –8.4)     –8.6 (–10.3 to –7.0)   –17.9*** (–18.9 to –16.8)    –18.2*** (–19.4 to –16.9)     –19.8*** (–20.9 to –18.8)    –19.9*** (–21.1 to –18.7)
HAQ–DI               –0.2 (–0.2 to –0.1)       –0.2 (–0.2 to –0.1)       –0.4*** (–0.5 to –0.4)          –0.5*** (–0.5 to –0.4)           –0.5*** (–0.6 to –0.5)          –0.5*** (–0.6 to –0.5)
DAS28-4-ESR      –0.8 (–1.0 to –0.7)       –0.7 (–0.9 to –0.5)       –1.8*** (–1.9 to –1.7)          –1.8*** (–1.9 to –1.7)           –2.0*** (–2.1 to –1.9)          –2.0*** (–2.2 to –1.9)
Pain VAS              –8.7 (–11.3 to –6.1)     –9.6 (–12.6 to –6.6)   –23.8*** (–25.8 to –21.8)    –23.8*** (–26.1 to –21.4)     –25.7*** (–27.7 to –23.7)    –27.3*** (–29.5 to –25.1)
*p < 0.05; **p < 0.001; ***p < 0.0001 (without multiplicity adjustment for exploratory analysis) vs placebo within the respective subgroup. aNote: patient
numbers given are from the FAS for ACR responses; however, patient numbers varied among outcome measures. Percentages are based on available data for
each outcome measure. ACR20/50/70: an improvement of  ≥ 20%, ≥ 50%, and ≥ 70%, respectively, in American College of Rheumatology criteria; BID: twice
daily; CDAI: Clinical Disease Activity Index; csDMARD: conventional synthetic disease-modifying antirheumatic drugs; DAS28-4-ESR: 28-joint Disease
Activity Score using the erythrocyte sedimentation rate; FAS: full analysis set; GC: glucocorticoids; HAQ-DI: Health Assessment Questionnaire–Disability
Index; LDA: low disease activity; LSM: least squares mean; NRI: nonresponder imputation; VAS: visual analog scale.
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therefore, may not be generalizable to patients starting GC
together with csDMARD, implying that caution must be
taken when comparing the results from our analysis to other
trials in which patients were GC-naive prior to the
commencement of the study. Further, it has previously been
reported that rheumatologists may be more likely to initiate
GC in patients with more severe RA39. Although the baseline
characteristics of patients in our analysis were generally
similar, it is possible that the patients with RA receiving GC
were less responsive to treatment than the patients who were
not initially receiving GC. An additional limitation of our
analysis is the estimation of GC dose using the proto-
col-required limits where the actual dose of GC was not
available. Differences in the effects of GC dose on efficacy
were also not explored. Further, the sample sizes of the study
populations were limited, particularly in the monotherapy
studies (ORAL Start and ORAL Solo), as was the length of the
followup period. The longer-term effects of concomitant GC
use on the efficacy and safety of tofacitinib are not yet known.
    The concomitant use of GC may not affect the clinical
efficacy of tofacitinib in MTX-naive, DMARD-IR, and
MTX-IR patients receiving tofacitinib as monotherapy or in
combination with background csDMARD. Further, the
radiographic efficacy of tofacitinib monotherapy in
MTX-naive patients did not appear to be affected by
concomitant GC use. In contrast, MTX in combination with
GC showed a trend of inhibiting radiographic progression to
a greater degree than MTX alone. Further research, in the
form of a randomized clinical trial evaluating efficacy in
tofacitinib-treated GC-naive patients with RA, with or
without concomitant oral GC of varying dose, would be
needed to definitively characterize the efficacy and safety
profile of tofacitinib in combination with GC.
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